Anzeige
Mehr »
Login
Montag, 27.09.2021 Börsentäglich über 12.000 News von 673 internationalen Medien
LUKRATIVE NEUVORSTELLUNG IM MEGA-WACHSTUMSMARKT
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9YT ISIN: ES0169501022 Ticker-Symbol: PMRA 
Tradegate
24.09.21
15:16 Uhr
79,74 Euro
+0,42
+0,53 %
Branche
Biotechnologie
Aktienmarkt
IBEX-35
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
78,6279,7826.09.
78,5079,6424.09.

Aktuelle News zur PHARMAMAR Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PHARMAMAR Aktie jetzt für 0€ handeln
MiPHARMA MAR, S.A.: The Company announces the approval of Zepzelca (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Singapore.2
14.09.PHARMA MAR, S.A.: The Company announces the approval of Zepzelca (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Australia2
01.09.PHARMA MAR, S.A.: The Company announces the approval of Zepzelca (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in the United Arab Emirates8
29.07.Spain's PharmaMar sales rise on demand for cancer treatments12
29.07.PHARMA MAR, S.A.: The Company informs of changes in the composition of the Appointments and Compensation and Sustainability Committee, and in the Audit Committee, as well as the amendments of the Board of Directors Regulations.2
29.07.PHARMA MAR, S.A.: The Company sends press release regarding first half 2021 results and announces a conference call with analysts and investors.5
28.07.PHARMA MAR, S.A.: COMP, from the EMA, has given its positive opinion for the approval of Orphan Drug status to Zepzelca (lurbinectedin) for the treatment of Mesothelioma8
26.05.Spain's PharmaMar says COVID-19 treatment shows clinical efficacy in trials27
05.05.PHARMA MAR, S.A.: The Company files first quarter 2021 financial information.15
29.04.Spain's regulator lets PharmaMar test treatment on COVID-19 patients14
29.04.PHARMA MAR, S.A.: The Company announces that it has obtained the authorization from the Spanish Agency for Medicines and Health Products (AEMPS) to initiate the Phase III NEPTUNO.5
23.04.PHARMA MAR, S.A.: The Company announces its licensing partner, Specialised Therapeutics Asia, Pte. Ltd. (STA) received marketing approval for Yondelis (trabectedin) by the Australian Therapeutic Goods Administration (TGA).5
15.04.PHARMA MAR, S.A.: The Company reports changes in the composition of its Board of Directors and of its Appointments and Compensation and Sustainability Committee.3
15.04.PHARMA MAR, S.A.: The Company informs about the dividend payment.6
15.04.PHARMA MAR, S.A.: It is reported that all proposed resolutions submitted by the Board to the General Shareholders' Meeting have been approved.3
15.04.PHARMA MAR, S.A.: Attached is a copy of the presentation to shareholders to be made at the General Shareholders' Meeting of Pharma Mar by the Chairman of the Company.1
15.04.European oncology group adds Pharma Mar's Lurbinectedin to treatment guidelines1
13.04.PHARMA MAR, S.A.: Axesor raises long-term credit rating of Pharma Mar.4
08.04.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between 01/01/2021 and 31/03/20216
03.12.20Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line1.902DUBLIN, Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1